A number of specific chromosomal abnormalities define the subgroups of multiple myeloma. In a meta-analysis of two genome-wide association studies of multiple myeloma including a total of 1,661 affected individuals, we investigated risk for developing a specific tumor karyotype. The t(11;14)(q13;q32) translocation in which CCND1 is placed under the control of the immunoglobulin heavy chain enhancer was strongly associated with the CCND1 c.870G>A polymorphism (P = 7.96 × 10 −11 ). These results provide a model in which a constitutive genetic factor is associated with risk of a specific chromosomal translocation.
Human 1.2M-Duo Custom_v1 Array BeadChips (Online Methods).
The German GWAS comprised the original 384 multiple myeloma cases recruited from the Heidelberg University Clinic plus an additional 698 affected individuals recruited from the same source. Genotype frequencies were compared with those in genotype data generated by the Heinz-Nixdorf Recall (HNR) study of 2,132 individuals 6 from the German population who had been genotyped using Illumina HumanOmni1-Quad BeadChips (Online Methods).
Genotype data were filtered on the basis of prespecified quality control measures. SNPs showing deviation from Hardy-Weinberg equilibrium with P < 1.0 × 10 −6 in controls or having call rate < 95% or minor allele frequency (MAF) < 1% were excluded. Samples were removed if closely related or if they were not of Northern and Western European descent (consistent with the CEU HapMap population) (Online Methods and Supplementary Figs. 1 and 2) . After filtering, 414,804 autosomal SNPs common to both case-control series remained (Supplementary Fig. 1 ).
To explore the relationship between SNP genotype and translocations involving the IGH@ locus (t(4;14) (p16;q32), t(11;14) (q13;q32) and others), as well as hyperdiploid status, we restricted our analysis to the 1,660 multiple myeloma cases with FISH and/or karyotype data ( Supplementary Fig. 1 ). Translocation data were available for 1,655 multiple myeloma cases, with 12% having t(4;14) and 17% having t (11;14) , and ploidy status was available for 1,535 cases, of whom 55% had hyperdiploidy (Supplementary Table 1) .
Before undertaking meta-analysis of the two GWAS by subtype, we searched for potential errors and biases in the data sets. Quantilequantile plots of χ 2 values for all cases against values from controls showed that there was limited inflation of the test statistics (genomic control inflation factor λ before and after EIGENSTRAT adjustment = 1.03, 1.01 and 1.17, 1.03 for the UK and German studies, respectively;
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma l e t t e r s Supplementary Fig. 3 ). Using data from the UK and German GWAS, we derived the combined odds ratio (OR) and confidence interval (CI) for each SNP under a fixed-effects model along with the associated P value for each multiple myeloma subtype (comparing case subtypes with all controls). Heterogeneity between different tumor subtypes was assessed by case-only analyses with the tumor characteristic set as the outcome variable.
Only one SNP, rs603965, showed a statistically significant association with multiple myeloma risk (at P < 5.0 × 10 −8 ) that was subtype specific. All other associations were generic, that is, not subtype specific. rs603965 genotype was associated with an OR of 1.82 for t (11;14) multiple myeloma (P = 7.96 × 10 −11 ; Table 1 and Supplementary  Table 2 ). Furthermore, case-only analysis provided evidence that supported the notion that the rs603965 association was specific to t(11;14) multiple myeloma (P = 2.07 × 10 −11 ). Because multiple myeloma is the result of the transformation of plasma cells localized in the bone marrow and because genotyping was performed on lymphocyte DNA obtained before chemotherapy in >80% of cases, it is highly unlikely that somatic changes influenced the study findings. To confirm the fidelity of the Illumina BeadChip genotypes for rs603965, we retyped all t (11;14) cases and a subset of the controls from both studies using orthogonal technologies (Supplementary Table 3) .
Associations between all other IGH@ translocations and hyperdiploid multiple myeloma were either nonsignificant (P > 0.05) or were generic, being nonsignificant in a case-only analysis. Because multiple myeloma subgroups were not mutually exclusive and a common control series was used, we performed a meta-analysis using ASSET (ASsociation analysis based on subSETs) 7 exploring all possible subsets of 'non-null' studies (testing whether subsets were negatively, positively or not associated). This method identifies the subset with the strongest association signal and accounts for the multiple tests required by the subset search (Online Methods). This analysis provided further strong support for the association of rs603965 with t(11;14) multiple myeloma (P = 6.20 × 10 −9 ; Supplementary Fig. 4) . rs603965 maps to a 62.4-kb region of linkage disequilibrium (LD) at 11q13.3 (69,462,910 bp) and is responsible for the c.870G>A polymorphism in CCND1 (encoding cyclin D1; MIM 168461). Additional support for the association at 11q13.3 was provided by rs649392 (P = 5.47 × 10 −9 ) and rs1352075 (P = 1.48 × 10 −8 ), which are in LD with rs603965 (r 2 = 0.47 and 0.66, respectively; Supplementary Table 2 ). Cyclin D1 is a component of the core cell cycle machinery, and higher levels are detected in many human cancers, including multiple myeloma. In addition to activating the cyclin-dependent kinases CDK4 and CDK6, cyclin D1 has kinase-independent functions in DNA repair, notably directly binding RAD51, a recombinase that drives homologous recombination 8, 9 . Overproduction of a D-group cyclin is a common feature of multiple myeloma, and, in the t(11;14) subtype, it is CCND1 that is upregulated through close proximity to the powerful Eµ enhancer of the IGH@ locus resulting from reciprocal translocation.
To further examine the relationship between 11q13.3 genotype and the risk of t(11;14) multiple myeloma, we imputed unobserved genotypes in the UK and German GWAS cases and controls using data from the 1000 Genomes Project (Online Methods). This analysis did not provide evidence for a stronger association than that of rs603965 ( Fig. 1 and Supplementary Table 4) . The results of conditional analysis provided a model in which rs603965 genotype was sufficient to capture the association at 11q13.3.
In multiple myeloma, immunoglobulin gene translocations are generated by abnormal class switch recombination (CSR) events occurring during the germinal center stage of B cell development. npg l e t t e r s Such abnormal CSR events are usually present in all clonal cells and are also detectable in monoclonal gammopathy of unknown significance (MGUS), a premalignant phase of multiple myeloma, consistent with their early development in multiple myeloma 3, 10 . Normal CSR involves recognition of switch (S) regions and double-strand break (DSB) DNA cleavage steps, which are driven by an activationinduced deaminase. DSBs are then repaired using translocationprone pathways not involving classical non-homologous end joining (NHEJ) 11 , which can result in reciprocal translocation to other DSBs located elsewhere in the genome. We therefore examined the relationship between the rs603965 genotype and the risk of MGUS in 155 German cases, 40 of whom were positive for the t(11;14) translocation. As with multiple myeloma, the frequency of the G allele was significantly higher in MGUS cases with t(11;14) than in those without the translocation (0.69 and 0.55, respectively; P = 0.03). This observation is, therefore, entirely consistent with the effect of rs603965 on t(11;14) multiple myeloma risk arising early in the evolution of the disease. However, the absence of an association between rs603965 and risk of translocations other than t(11;14) suggests that the effect of the genotype is not entirely mediated through the facilitation of errors in CSR. The t(11;14) translocation is also a feature of other B cell malignancies, notably mantle cell lymphoma (MCL), in which the translocation is caused by abnormal VDJ recombination at the IGH@ locus. However, the breakpoints in MCL are to some extent clustered, whereas the breakpoints in t(11;14) multiple myeloma are heterogeneous, occurring over several hundred kilobases in the region upstream of CCND1 (ref. 12). To explore the possibility that rs603965 genotype might influence the advent of a t(11:14) translocation in MCL, we studied 45 German MCL cases and compared allele frequencies at rs603965 with those in the 2,124 controls. Allele frequencies were not different between the cases and controls (the frequency of the G allele was 0.54 in cases and 0.53 in controls; P = 0.85), a finding consistent with data from a recently reported analysis of 121 MCL cases and 1,780 controls that also showed no evidence of a relationship between rs603965 genotype and MCL risk (P = 0.95) 13 . The absence of an association is consistent with different etiological bases for t(11;14) multiple myeloma and MCL 11, 14 .
Deregulation of a D-group cyclin is a key feature of multiple myeloma and constitutes a major component of the TC (translocation cyclin D) classification of this disorder. CCND1 is highly overexpressed in t(11;14) multiple myeloma as a consequence of its rearrangement in close proximity to the immunoglobulin enhancer region, and, in addition, it is overexpressed in the majority of hyperdiploid myeloma cases via an alternate mechanism. Normal plasma cells are non-cycling and, as a consequence, do not express cyclin D1; however, multiple myeloma results from the transformation of a plasmablast during CSR. The level of expression of cyclin D1 at this stage of plasma cell development is unknown. We found no association between rs603965 genotype and the overall level of CCND1 mRNA expression in CD138-expressing primary multiple myelomas or lymphoblastoid cell lines (Supplementary Table 5 ). rs603965 genotype has, however, been shown to influence the alternative splicing of CCND1 mRNA, and the c.870G allele creates an optimal splice donor site at the exon 4-intron 4 boundary, resulting in production of the cyclin D1a transcript 9 . By contrast, the c.870A allele hinders splicing, allowing for read through into intron 4 and the production of the variant cyclin D1b transcript 9 . Although c.870A is preferentially associated with cyclin D1b production, the A allele is not fully penetrant 9 . In CD138-expressing plasma cells, we found a significant allele-specific correlation between the c.870G genotype and cyclin D1a/cyclin D1b transcript ratio in all multiple myelomas and in samples restricted for hyperdiploidy or t(11;14) (Supplementary Fig. 5 ).
Over the last decade, the CCND1 c.870G>A polymorphism has been variously reported to confer risk for a large number of cancers, with the majority of studies linking the c.870A allele to cancer risk 9, 15 . The molecular basis for the association between the c.870G allele and an almost doubled risk of developing t(11;14) multiple myeloma remains to be established. The two isoforms of cyclin D1 differ in their fundamental biological and biochemical properties 16 . Cyclin D1b conveys greater transforming capacity 16 but lacks the DNA damage response associated with cyclin D1a 17 . Although cyclin D1b seems to have no cell regulatory properties in B lymphocytes 18 , both isoforms are detectable in multiple myeloma cell lines and primary patient myeloma cells, although their respective roles in myelomagenesis remain unresolved 19 . One potential model is that the c.870G allele facilitates clonal expansion after the translocation event and overexpression of CCND1, but evidence supporting differential oncogenic potentials for cyclin D1a and cyclin D1b is lacking. Moreover, we found no evidence for an association of cyclin D1a with hyperdiploid multiple myeloma. The lack of an association of CCND1 genotype with other subgroups of multiple myeloma, which are also characterized by immunoglobulin translocations deregulating other genes, argues against the rs603965 genotype facilitating the development of translocation through a general mechanism. Collectively, our data are compatible with the c.870G genotype affecting the early evolution of t(11;14) multiple myeloma.
In conclusion, our findings show a relationship between CCND1 c.870G>A and risk of t(11;14) multiple myeloma and provide the first evidence to our knowledge of genetic variation being a determinant of the risk of acquiring a specific chromosomal translocation. This association was not found in the original GWAS owing to the low frequency of the t(11;14) subtype, and, thus, our findings underscore the value of conducting subtype-specific analyses for cancer. 
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GWAS.
The UK GWAS has previously been described. Briefly, the study was based on multiple myeloma cases (ICD-10 C90.0; 469 males; mean age at diagnosis of 63.9 years, s.d. of 9.9 years) ascertained through the UK MRC Myeloma IX trial 20 . All cases were UK residents. For controls, we used publicly accessible data generated by the Wellcome Trust Case Control Consortium from the 1958 Birth Cohort (58C; also known as the National Child Development Study) 5 and NBS. Genotyping of both sets of controls was conducted using Illumina Human 1-2M-Duo Custom_v1 Array chips.
The German GWAS comprised 384 multiple myeloma cases who were the subject of a previous publication and an additional series of 698 multiple myeloma cases (388 males and 310 females; mean age at diagnosis of 59 years, s.d. of 9.3 years) recruited at the University Clinic, Heidelberg. As before, the additional cases were genotyped using Illumina HumanOmniExpress-12 v1.0 arrays according to the manufacturer's protocols. DNA samples with a GenCall score of <0.25 at any locus were considered no calls. A SNP was deemed to have failed if <95% of DNA samples generated a genotype at the locus. For controls, we used genotype data on 2,132 healthy individuals enrolled in the HNR study 6 .
MCL cases. rs603965 genotype was determined in 45 German cases with MCL recruited from the University Clinic, Heidelberg (37 males; mean age at diagnosis of 60.3 years, s.d. of 8.1 years).
MGUS cases.
Analysis was based on 155 MGUS cases ascertained through the University Clinic, Heidelberg (80 males; mean age at diagnosis of 59.5 years, s.d. of 12.0 years).
Validation of SNP genotypes.
To confirm the accuracy of Illumina BeadChip rs603965 genotypes in cases and controls, we (i) sequenced all the German t(11;14) cases using ABI310 technology (Applied Biosystems) and (ii) genotyped all German t(11;14) cases and a subset of controls and all UK t (11;14) cases and a subset of controls using KASPar Allele-Specific PCR (LCG Genomics) (Supplementary Table 3) . PCR primer sequences and details of conditions are available upon request.
Statistical and bioinformatics analyses. The same quality control metrics on the new German GWAS data were applied as in our previous multiple myeloma study 4 . Briefly, samples were excluded if <95% of SNPs were successfully genotyped (10 samples) or if identity-by-state (IBS) probabilities for pairs of samples were ≥0.80 (13 samples). To identify individuals of divergent ancestry, we conducted a principal-components analysis using smartPCA from the EIGENSTRAT 21 package and a pruned SNP set 22 . We excluded 70 individuals from analyses. SNPs having MAF of <1% or call rate of <95% were excluded. SNPs showing departure from Hardy-Weinberg equilibrium in controls at P < 1 × 10 −6 were also excluded.
Main analyses were undertaken using R (v2.6), Stata v.10, PLINK (v1.06) and EIGENSTRAT software. The association between each SNP and the cytogenetic subgroup of multiple myeloma was assessed by the Cochran-Armitage trend test. The possibility of differential genotyping of cytogenetic subgroups and controls was evaluated using quantile-quantile plots of test statistics. ORs and associated 95% CIs were calculated by unconditional logistic regression. To fully examine the effects of population substructure on our findings, we performed principal-components analysis using EIGENSTRAT 21 software. Meta-analysis was first conducted using standard methods 23 . The Cochran's Q statistic was calculated to test for heterogeneity 23 , and the I 2 statistic was calculated to quantify the proportion of the total variation due to heterogeneity. I 2 values of ≥75% were considered to be characteristic of large heterogeneity 24 .
Meta-analysis was also performed using the R statistical package ASSET, which explores all possible subsets of non-null studies to identify the strongest association signal and then evaluates the significance of the signal while accounting for the multiple tests required by the subset search 7 .
Prediction of the ungenotyped SNPs was carried out using IMPUTEv2 on the basis of the 1000 Genomes Project phase 1 integrated variant set (b37) from March 2012. Imputed data were analyzed using SNPTEST v2 to account for uncertainties in SNP prediction. LD metrics were calculated in PLINK using 1000 Genomes Project data and plotted using SNAP. LD blocks were defined according to HapMap recombination rate (centimorgans per megabase), as determined using the Oxford recombination hotspots 25 and the previously set distribution of CIs 26 .
FISH. FISH and ploidy classification of UK samples was conducted using previously described methodology 27 . FISH and ploidy classification of German samples was performed as previously described 28 . The XL IGH Break Apart probe (MetaSystems) was used to detect any IGH@ translocation in German samples.
Relationship between SNP genotype and mRNA expression. To look for a relationship between rs603965 genotype and CCND1 expression in multiple myeloma (in plasma cells selected for CD138 expression), we made use of Affymetrix Human Genome U133 Plus 2.0 array data we previously generated on plasma cells from 192 multiple myeloma cases from the MRC Myeloma IX trial 29 . To look for a relationship between SNP genotype and expression levels in lymphocytes, we made use of publicly available expression data generated on lymphoblastoid cell lines from Geneva GenCord individuals 30 , the MuTHER resource 31 and HapMap 3 (ref. 32) using Sentrix Human-6 Expression BeadChips (Illumina) 33, 34 .
To quantitatively evaluate the expression of the cyclin D1a and D1b transcripts in CD138-expressing plasma cells, total RNA was extracted using an RNA/DNA mini kit or an AllPrep kit (Qiagen), and cDNA was synthesized using SuperScript II reverse transcriptase with Oligo(dT) [12] [13] [14] [15] [16] [17] [18] primer (Invitrogen) according to the manufacturer's instructions. Custom PCR primers were designed with Primer3 to the exon 4-intron 4 boundary (short isoform, cyclin D1b) and used together with previously described primers to the 3 UTR (long isoform, cyclin D1a) 35 (Supplementary Table 6 ). cDNA was amplified using a 7500 real-time PCR cycler with SYBR Green Reagents according to the manufacturer's protocol. The relative quantities of the CCND1 isomers were determined by the comparative C T (∆∆C T ) method using 7500 Software version v2.0.6 (Applied Biosystems).
